LINC00173: A Drug Target / Disease Biomarker (G100287569)

Target Name: LINC00173

NCBI ID: G100287569

LINC00173

Other Name(s): Long intergenic non-protein coding RNA 173, transcript variant 1 | long intergenic non-protein coding RNA 173 | NCRNA00173 | FLJ42957

LINC00173: A Drug Target / Disease Biomarker

LINC00173 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell cycle and is involved in the development and progression of various diseases, including cancer.

LINC00173 is a small non-coding RNA molecule that is approximately 200 amino acids long. It is expressed in a variety of tissues and cells and is involved in the regulation of the cell cycle. The cell cycle is the process by which cells grow, divide, and replicate their genetic material. LINC00173 is a key regulator of this process and is involved in the control of cell cycle progression.

One of the key functions of LINC00173 is to regulate the length of the telomeres, which are the protective caps at the end of chromosomes that prevent chromosomes from fusing with one another. Telomeres are naturally shortened each time a cell divides, and the length of telomeres can be affected by a variety of factors, including the age of the cell, the level of stress in the cell, and the presence of certain diseases. LINC00173 is involved in the regulation of telomere length and has been shown to play a role in the development of various diseases, including cancer.

In addition to its role in regulating the cell cycle, LINC00173 has also been shown to be involved in the regulation of gene expression. It interacts with a variety of transcription factors and can modulate the activity of these factors, influencing the expression of genes involved in various cellular processes. This is important because changes in gene expression can have a significant impact on the development and progression of diseases.

The potential drug target status of LINC00173 is supported by its ability to interact with a variety of transcription factors and its involvement in the regulation of cellular processes that are involved in the development and progression of various diseases. Many drugs that are currently in use target proteins that are involved in these processes and can have significant benefits for the treatment of these diseases. By targeting LINC00173, researchers may be able to develop new treatments for a variety of diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 173

The "LINC00173 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00173 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets